Bayer’s prostate cancer drug clears FDA three months early; a House committee is pressing the regulator for employment transparancy; and Ranbaxy takes a multi-million dollar hit over violations
Roche and Isis pair up for Huntingtons, Vital’s prescription vision app gets approved, FDA approval revives maligned morning sickness drug, Gilead sends hep C therapy to regulators and Sanofi’s emerging market exposure grabs attention.
Sanofi Pasteur scored a pharma first this past winter by offering “Shazam” technology as a way for viewers to interact with TV commercials for its Fluzone Intradermal influenza vaccine—and to find out where they could get the new shot.
Shire expands its pipeline yet again, AthenaHealth stretches its HCP-patient reach, FDA delays GSK’s bird-flu vaccine, Novartis wins approval for cystic fibrosis inhaler
Nature releases the Antibodypedia’s seventh generation, Elsevier adds more board review apps, and how redefining “senior” may not save money in the long run